1-ethyl-6-bromo-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid | 70458-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-ethyl-6-bromo-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid
• 英文别名: 6-bromo-1-ethyl-7-(4-methylpiperazinyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid；6-bromo-1-ethyl-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid；6-bromo-1-ethyl-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
• CAS: 70458-87-6
• 化学式: C₁₇H₂₀BrN₃O₃
• 分子量: 394.268
• InChiKey: BMIRJNRBWKGXAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-bromo-7-chloro-1-ethyl-4-oxo-1,4-dihydro-3-ethoxycarbonylquinoline 在 sodium hydroxide 作用下， 反应 7.0h， 生成 1-ethyl-6-bromo-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  抗菌的6,7-和7,8-二取代的1-烷基-1,4-二氢-4-氧代喹啉-3-羧酸的结构活性关系。

  摘要：

  先前在抗菌单取代的1-乙基-1,4-二氢-4-氧代喹啉3-羧酸中进行的定量和定性结构活性研究促使我们合成了6,7,8-多取代的化合物。在本文中，描述了6,7-和7,8-二取代化合物及其衍生物的制备和抗菌活性。在这些化合物中，1-乙基-6-氟-1,4-二氢-4-氧代-7-（1-哌嗪基）喹啉-3-羧酸（34）具有许多显着的活性，并且比草酸（ 84）对抗革兰氏阳性和革兰氏阴性细菌。讨论了构效关系。

  DOI：

  10.1021/jm00186a014

文献信息

• [EN] AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INFLAMMATOIRES AYANT UNE STRUCTURE BASÉE SUR LA 4(1H)-QUINOLONE
  申请人：UCL BUSINESS PLC

  公开号：WO2015189560A1

  公开（公告）日：2015-12-17

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of a cardiovascular disease or of an inflammatory disease or condition:

  本发明提供了一种式I的化合物，其互变异构体，或其药用可接受的盐或N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或症状。
• Substituted quinoline carboxylic acid derivatives
  申请人：Kyorin Seiyaku Kabushiki Kaisha

  公开号：US04448962A1

  公开（公告）日：1984-05-15

  This invention relates to new compounds of value as antibacterial agents. More particularly, it relates to quinoline carboxylic acid derivatives, the hydrates and the acid or alkali addition salts thereof.

  这项发明涉及作为抗菌剂有价值的新化合物。更具体地说，它涉及喹啉羧酸衍生物，以及其水合物和酸性或碱性加盐。
• 1,4-Dihydro-quinoline-3-carboxylic acid derivatives, process for their
  申请人：Laboratorie Roger Bellon

  公开号：US04292317A1

  公开（公告）日：1981-09-29

  New 7-dialkylamino-1-substituted-6-halogeno-4-oxo-1,4-dihydroquinoline-3 carboxylic acids of the formula: ##STR1## wherein the R.sub.1 substituent is methyl, ethyl, vinyl or allyl and non-toxic pharmaceutically acceptable acid addition salts thereof. These compounds are useful as antibacterial agents. Also disclosed are processes for preparing the compounds.

  新的7-二烷基氨基-1-取代-6-卤代-4-氧基-1,4-二氢喹啉-3-羧酸的化学式如下：其中R.sub.1取代基为甲基、乙基、乙烯基或烯丙基，以及其非毒性药用酸盐。这些化合物可用作抗菌剂。还公开了制备这些化合物的方法。
• KOGA, HIROSHI;ITOH, AKIRA;MURAYAMA, SATOSHI;SUZUE, SEIGO;IRIKURA, TSUTOMU, J. MED. CHEM., 1980, 23, N 12, 1358-1363
  作者：KOGA, HIROSHI、ITOH, AKIRA、MURAYAMA, SATOSHI、SUZUE, SEIGO、IRIKURA, TSUTOMU

  DOI：——

  日期：——
• AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE
  申请人：UCL Business PLC

  公开号：US20170066722A1

  公开（公告）日：2017-03-09

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR 3 ; X is N or CR 4 ; Y is N or CR 5 ; Z is N or CR 6 ; B is —(C═O)R 1 , a 5- to 10-membered heteroaryl group, or a group -L′″-NRR′, wherein R and R′ are the same or different and each represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group; R 1 is a 5- to 10-membered heterocyclyl group, or —OR′, wherein R′ is a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group, or R 1 is a proteinogenic α amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the α amino group, which amino acid is optionally esterified at the α carboxylic acid group with a C 1 -C 6 alkyl group or a C 6 -C 10 aryl group, or R 1 is —NR″R′″, —NR IV -L′″-CONR″R′″, or —NR IV -L′″-COOR, wherein R, R″, R′″ and R IV are the same or different and each represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group; either (a) W is N and R 9 and R 2 together form a bond, or (b) W is CR 8 , R 8 and R 9 together form a bond and R 2 is a hydrogen atom, or a C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl, -L′-A 2 , C 3 -C 10 cycloalkyl, or —COOR′ group, wherein R′ is a hydrogen atom or C 1 -C 6 alkyl group, or, when Z is a moiety CR 6 , R 2 may form, together with R 6 and the carbon and nitrogen atoms which connect R 2 and R 6 in the formula (I), a 5- to 6-membered heterocyclic ring; R 3 is a hydrogen atom, a halogen atom, or a hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, nitro, or —NR′R″ group, wherein R′ and R″ are the same or different and each represent a hydrogen atom or C 1 -C 6 alkyl group; R 4 and R 5 are the same or different and each represent a hydrogen atom, a halogen atom, or a hydroxyl, C 1 -C 8 alkyl, C 1 -C 8 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, nitro, —NR′R″, —CO 2 R′″, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, 5 to 10-membered heterocyclyl, or —CO—(C 1 -C 6 alkyl) group, wherein R′, R″ and R′″ are the same or different and each represent a hydrogen atom or C 1 -C 6 alkyl group, or R 4 and R 5 and the carbon atoms bonded to R 4 and R 5 together form a 5- to 6-membered heterocyclic ring; R 6 is a hydrogen atom, a halogen atom, or a C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy or —CO 2 R′ group, wherein R′ is hydrogen or C 1 -C 6 alkyl, or, when W is a moiety CR 8 , R 6 may form, together with R 2 and the carbon and nitrogen atoms which connect R 6 and R 2 in the formula (I), a 5- to 6-membered heterocyclic ring; R 7 is a hydrogen atom, a halogen atom, or a C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl group, A 2 represents a C 6 -C 10 aryl or 5- to 10-membered heteroaryl group; L′, and L′″ are the same or different and each represent a C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene group; said aryl, heteroaryl, cycloalkyl and heterocyclyl groups being unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, —SOR, —SO 2 R, —NR′R″, —NR′(C═O)R″, —COOR, nitro and cyano substituents, wherein R, R′ and R″ are the same or different and each represents a hydrogen atom or C 1 -C 4 alkyl group.